Van der Horst-Bruinsma IE - Search Results

1

C-reactive protein polymorphisms influence serum CRP-levels independent of disease activity in ankylosing spondylitis.

Claushuis TA, de Vries MK, van der Weijden MA, Visman IM, Nurmohamed MT, Twisk JW, Van der Horst-Bruinsma IE, Crusius JB. Claushuis TA, et al. Clin Exp Rheumatol. 2015 Mar-Apr;33(2):159-65. Epub 2015 Jan 20. Clin Exp Rheumatol. 2015. PMID: 25603416

2

Increased risk of developing ankylosing spondylitis among first-born children.

Baudoin P, van der Horst-Bruinsma IE, Dekker-Saeys AJ, Weinreich S, Bezemer PD, Dijkmans BA. Baudoin P, et al. Arthritis Rheum. 2000 Dec;43(12):2818-22. doi: 10.1002/1529-0131(200012)43:12<2818::AID-ANR23>3.0.CO;2-F. Arthritis Rheum. 2000. PMID: 11145041 Free article.

3

Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs.

van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA. van der Horst-Bruinsma IE, et al. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S67-70. Clin Exp Rheumatol. 2002. PMID: 12463451 Review.

4

Dutch patients with familial and sporadic ankylosing spondylitis do not differ in disease phenotype.

Paardt Mv, Dijkmans B, Giltay E, van der Horst-Bruinsma I. Paardt Mv, et al. J Rheumatol. 2002 Dec;29(12):2583-4. J Rheumatol. 2002. PMID: 12465156

5

Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis.

van der Paardt M, Crusius JB, García-González MA, Baudoin P, Kostense PJ, Alizadeh BZ, Dijkmans BA, Peña AS, van der Horst-Bruinsma IE. van der Paardt M, et al. Rheumatology (Oxford). 2002 Dec;41(12):1419-23. doi: 10.1093/rheumatology/41.12.1419. Rheumatology (Oxford). 2002. PMID: 12468823

6

CARD15 gene mutations are not associated with ankylosing spondylitis.

van der Paardt M, Crusius JB, de Koning MH, Murillo LS, van de Stadt RJ, Dijkmans BA, Peña AS, van der Horst-Bruinsma IE. van der Paardt M, et al. Genes Immun. 2003 Jan;4(1):77-8. doi: 10.1038/sj.gene.6363914. Genes Immun. 2003. PMID: 12595906

7

Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis.

van Denderen JC, van der Horst-Bruinsma I, Bezemer PD, Dijkmans BA. van Denderen JC, et al. J Rheumatol. 2003 Jul;30(7):1558-60. J Rheumatol. 2003. PMID: 12858458 Clinical Trial.

8

The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis.

Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt RJ, de Koning MH, Dijkmans BA. Jansen LM, et al. J Rheumatol. 2003 Aug;30(8):1691-5. J Rheumatol. 2003. PMID: 12913923

9

[Thrombosis prevention in orthopaedic surgery: clinical practice in the Netherlands in 2002].

Schonenberg D, van Meeteren M, Nelissen RG, van der Horst-Bruinsma IE, Pöll RG, Nurmohamed MT. Schonenberg D, et al. Ned Tijdschr Geneeskd. 2003 Sep 20;147(38):1856-60. Ned Tijdschr Geneeskd. 2003. PMID: 14533499 Dutch.

10

Comparison of the baseline disease activity of early oligo- and polyarthritis in sequential years.

Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Lard LR, Hazes JM, Huizinga TW, Dijkmans BA. Jansen LM, et al. Clin Exp Rheumatol. 2004 Jul-Aug;22(4):447-52. Clin Exp Rheumatol. 2004. PMID: 15301242

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

203 results

Search Page